1
|
Lisek M, Tomczak J, Swiatek J, Kaluza A, Boczek T. Histone Deacetylases in Retinoblastoma. Int J Mol Sci 2024; 25:6910. [PMID: 39000021 PMCID: PMC11241206 DOI: 10.3390/ijms25136910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2024] [Revised: 06/16/2024] [Accepted: 06/19/2024] [Indexed: 07/14/2024] Open
Abstract
Retinoblastoma, a pediatric ocular malignancy, presents significant challenges in comprehending its molecular underpinnings and targeted therapeutic approaches. The dysregulated activity of histone deacetylases (HDACs) has been associated with retinoblastoma pathogenesis, influencing critical cellular processes like cell cycle regulation or retinal ganglion cell apoptosis. Through their deacetylase activity, HDACs exert control over key tumor suppressors and oncogenes, influencing the delicate equilibrium between proliferation and cell death. Furthermore, the interplay between HDACs and the retinoblastoma protein pathway, a pivotal aspect of retinoblastoma etiology, reveals a complex network of interactions influencing the tumor microenvironment. The examination of HDAC inhibitors, encompassing both established and novel compounds, offers insights into potential approaches to restore acetylation balance and impede retinoblastoma progression. Moreover, the identification of specific HDAC isoforms exhibiting varying expression in retinoblastoma provides avenues for personalized therapeutic strategies, allowing for interventions tailored to individual patient profiles. This review focuses on the intricate interrelationship between HDACs and retinoblastoma, shedding light on epigenetic mechanisms that control tumor development and progression. The exploration of HDAC-targeted therapies underscores the potential for innovative treatment modalities in the pursuit of more efficacious and personalized management strategies for this disease.
Collapse
Affiliation(s)
- Malwina Lisek
- Department of Molecular Neurochemistry, Medical University of Lodz, 90-419 Lodz, Poland; (J.T.); (J.S.); (A.K.)
| | | | | | | | - Tomasz Boczek
- Department of Molecular Neurochemistry, Medical University of Lodz, 90-419 Lodz, Poland; (J.T.); (J.S.); (A.K.)
| |
Collapse
|
2
|
Bisen AC, Dubey A, Agrawal S, Biswas A, Rawat KS, Srivastava S, Bhatta RS. Recent updates on ocular disease management with ophthalmic ointments. Ther Deliv 2024; 15:463-480. [PMID: 38888757 DOI: 10.1080/20415990.2024.2346047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Accepted: 04/18/2024] [Indexed: 06/20/2024] Open
Abstract
Ophthalmic diseases can result in permanent vision loss and blindness. Convenient topical and systemic treatments are preferred to address these sight-threatening conditions. However, the unique anatomy of the eye presents challenges for drug delivery. Various ophthalmic ointment formulations have been developed to enhance bioavailability in the eye to prolong residence time and improve corneal permeability. This article explores a wide range of ocular diseases affecting individuals globally and how ointments are used to manage them. From eye to ocular barriers, this review focuses on published scientific research and formulation strategies for severe ocular complications using conventional topical ointments. Additionally, it delves through patented technologies and marketed formulations supporting the use of ointments in ocular drug delivery.
Collapse
Affiliation(s)
- Amol Chhatrapati Bisen
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India
- Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, 201002, Uttar Pradesh, India
- Sophisticated Analytical Instrument Facility and Research, CSIR-Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India
| | - Ayush Dubey
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India
- School of Pharmaceutical Sciences, CSJM University, Kanpur, 208024, Uttar Pradesh, India
| | - Sristi Agrawal
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India
- Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, 201002, Uttar Pradesh, India
| | - Arpon Biswas
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India
| | - Kundan Singh Rawat
- Prof. Rajendra Singh Nanoscience & Chemistry D.S.B. Campus, Kumaun University, Nainital, 263001, Uttarakhand, India
| | - Saurabh Srivastava
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India
- School of Pharmaceutical Sciences, CSJM University, Kanpur, 208024, Uttar Pradesh, India
| | - Rabi Sankar Bhatta
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India
- Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, 201002, Uttar Pradesh, India
| |
Collapse
|
3
|
Haase A, Miroschnikov N, Klein S, Doege A, Dünker N, Van Meenen D, Junker A, Göpferich A, Apaolaza PS, Busch MA. New retinoblastoma (RB) drug delivery approaches: anti-tumor effect of atrial natriuretic peptide (ANP)-conjugated hyaluronic-acid-coated gold nanoparticles for intraocular treatment of chemoresistant RB. Mol Oncol 2024; 18:832-849. [PMID: 38217258 PMCID: PMC10994242 DOI: 10.1002/1878-0261.13587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 11/02/2023] [Accepted: 01/04/2024] [Indexed: 01/15/2024] Open
Abstract
Intraocular drug delivery is a promising approach for treatment of ocular diseases. Chemotherapeutic drugs used in retinoblastoma (RB) treatment often lead to side effects and drug resistances. Therefore, new adjuvant therapies are needed to treat chemoresistant RBs. Biocompatible gold nanoparticles (GNPs) have unique antiangiogenic properties and can inhibit cancer progression. The combination of gold and low-molecular-weight hyaluronan (HA) enhances the stability of GNPs and promotes the distribution across ocular barriers. Attached to HA-GNPs, the atrial natriuretic peptide (ANP), which diminishes neovascularization in the eye, is a promising new therapeutic agent for RB treatment. In the study presented, we established ANP-coupled HA-GNPs and investigated their effect on the tumor formation potential of chemoresistant RB cells in an in ovo chicken chorioallantoic membrane model and an orthotopic in vivo RB rat eye model. Treatment of etoposide-resistant RB cells with ANP-HA-GNPs in ovo resulted in significantly reduced tumor growth and angiogenesis compared with controls. The antitumorigenic effect could be verified in the rat eye model, including a noninvasive application form via eye drops. Our data suggest that ANP-HA-GNPs represent a new minimally invasive, adjuvant treatment option for RB.
Collapse
Affiliation(s)
- André Haase
- Department of Neuroanatomy, Center for Translational Neuro‐ and Behavioral Sciences (C‐TNBS), Institute for Anatomy IIUniversity of Duisburg‐Essen, Medical FacultyGermany
| | - Natalia Miroschnikov
- Department of Neuroanatomy, Center for Translational Neuro‐ and Behavioral Sciences (C‐TNBS), Institute for Anatomy IIUniversity of Duisburg‐Essen, Medical FacultyGermany
| | - Stefan Klein
- Department of Neuroanatomy, Center for Translational Neuro‐ and Behavioral Sciences (C‐TNBS), Institute for Anatomy IIUniversity of Duisburg‐Essen, Medical FacultyGermany
| | - Annika Doege
- Department of Neuroanatomy, Center for Translational Neuro‐ and Behavioral Sciences (C‐TNBS), Institute for Anatomy IIUniversity of Duisburg‐Essen, Medical FacultyGermany
| | - Nicole Dünker
- Department of Neuroanatomy, Center for Translational Neuro‐ and Behavioral Sciences (C‐TNBS), Institute for Anatomy IIUniversity of Duisburg‐Essen, Medical FacultyGermany
| | - Dario Van Meenen
- Department of Neuroanatomy, Center for Translational Neuro‐ and Behavioral Sciences (C‐TNBS), Institute for Anatomy IIUniversity of Duisburg‐Essen, Medical FacultyGermany
| | - Andreas Junker
- Institute of NeuropathologyUniversity of Duisburg‐Essen, Medical FacultyGermany
| | - Achim Göpferich
- Department of Pharmaceutical TechnologyUniversity of RegensburgGermany
| | - Paola Stephanie Apaolaza
- Type 1 Diabetes Pathology Research Unit, Institute of Diabetes ResearchHelmholtz Centre MunichGermany
| | - Maike Anna Busch
- Department of Neuroanatomy, Center for Translational Neuro‐ and Behavioral Sciences (C‐TNBS), Institute for Anatomy IIUniversity of Duisburg‐Essen, Medical FacultyGermany
| |
Collapse
|
4
|
Silva-Teixeira R, Laranjo M, Lopes B, Almeida-Ferreira C, Gonçalves AC, Rodrigues T, Matafome P, Sarmento-Ribeiro AB, Caramelo F, Botelho MF. Plasma activated media and direct exposition can selectively ablate retinoblastoma cells. Free Radic Biol Med 2021; 171:302-313. [PMID: 34022401 DOI: 10.1016/j.freeradbiomed.2021.05.027] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Revised: 05/06/2021] [Accepted: 05/16/2021] [Indexed: 01/23/2023]
Abstract
A new therapy based on atmospheric plasma, the fourth state of matter, has raised the medical community's attention by circumventing many undesirable effects of old anticancer treatments. This work aimed to evaluate the effect, selectivity, and mechanisms of action of cold atmospheric plasma (CAP) in human retinoblastoma cells. An electronic device was designed to generate CAP in the open air, 2 mm above seeded cell cultures. Three approaches were performed: direct use of CAP, plasma-activated media (PAM), and conditioned media (CM). Timely-resolved output voltage measurement, emission spectroscopy, and quantification of reactive species (RS) of PAM were performed. To evaluate cytotoxicity and selectivity, similarly treated Y79, fibroblasts HFF1, and retinal RPE-D407 cells were assessed. After 60 s of direct CAP treatment, the metabolic activity of retinoblastoma cells decreased more than 50%, mainly due to apoptosis, while HFF1 and RPE-D407 remained viable. Similar results were obtained with indirect treatment (PAM and CM). Cell survival was reduced, and cells accumulated in S and G2/M phases; however, no DNA strand breaks were detected. Regarding RS, plasma increased extracellular and intracellular concentrations of peroxides and nitric oxide, despite glutathione activation and lack of success in reverting cytotoxicity with some RS inhibitors. RS increase comes in two timely distant waves, the first one originating from the plasma itself with secondary solubilization and passive diffusion, the second wave deriving from the mitochondrion. The addition of low doses of carboplatin to CAP-treated cells resulted in a significant increase in cytotoxicity compared with either regimen alone. Additionally, maximal antiangiogenic effects were obtained with 60 s of plasma exposure. Direct and indirect treatment with CAP might be a selective therapy with the potential to target tumour cells and supporting the microenvironment.
Collapse
Affiliation(s)
- Rafael Silva-Teixeira
- University of Coimbra, Faculty of Medicine, Institute of Biophysics, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal; Department of Cardiology, Hospital Center of Vila Nova de Gaia / Espinho, EPE, Rua Conceição Fernandes, 4434-502, Vila Nova de Gaia, Portugal; University of Coimbra, Institute for Clinical and Biomedical Research (iCBR), Area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal.
| | - Mafalda Laranjo
- University of Coimbra, Faculty of Medicine, Institute of Biophysics, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal; University of Coimbra, Institute for Clinical and Biomedical Research (iCBR), Area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal; University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal; Clinical and Academic Centre of Coimbra, Coimbra, Portugal.
| | - Beatriz Lopes
- University of Coimbra, Faculty of Medicine, Institute of Biophysics, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal.
| | - Catarina Almeida-Ferreira
- University of Coimbra, Faculty of Medicine, Institute of Biophysics, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal.
| | - Ana Cristina Gonçalves
- University of Coimbra, Institute for Clinical and Biomedical Research (iCBR), Area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal; University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal; Clinical and Academic Centre of Coimbra, Coimbra, Portugal; University of Coimbra, Faculty of Medicine, Laboratory of Oncobiology and Hematology, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal.
| | - Tiago Rodrigues
- University of Coimbra, Faculty of Medicine, Institute of Physiology, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal.
| | - Paulo Matafome
- University of Coimbra, Institute for Clinical and Biomedical Research (iCBR), Area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal; University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal; Clinical and Academic Centre of Coimbra, Coimbra, Portugal; University of Coimbra, Faculty of Medicine, Institute of Physiology, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal.
| | - Ana Bela Sarmento-Ribeiro
- University of Coimbra, Institute for Clinical and Biomedical Research (iCBR), Area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal; University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal; Clinical and Academic Centre of Coimbra, Coimbra, Portugal; University of Coimbra, Faculty of Medicine, Laboratory of Oncobiology and Hematology, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal.
| | - Francisco Caramelo
- University of Coimbra, Faculty of Medicine, Institute of Biophysics, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal; University of Coimbra, Institute for Clinical and Biomedical Research (iCBR), Area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal; University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal; Clinical and Academic Centre of Coimbra, Coimbra, Portugal.
| | - Maria Filomena Botelho
- University of Coimbra, Faculty of Medicine, Institute of Biophysics, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal; University of Coimbra, Institute for Clinical and Biomedical Research (iCBR), Area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal; University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal; Clinical and Academic Centre of Coimbra, Coimbra, Portugal.
| |
Collapse
|
5
|
Park SB, Jung SH, Jin H, Kim SJ, Ryu Y, Lee KJ, Kim B, Shin HJ, Won KJ. Bioluminescence Imaging of Matrix Metalloproteinases-2 and -9 Activities in Ethanol-injured Cornea of Mice. In Vivo 2021; 35:1521-1528. [PMID: 33910830 DOI: 10.21873/invivo.12405] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Revised: 02/16/2021] [Accepted: 02/17/2021] [Indexed: 12/17/2022]
Abstract
BACKGROUND/AIM This study aimed to investigate the usefulness of in vivo bioluminescence imaging (BLI) to examine the role of matrix metalloproteinases (MMP)-2 and MMP-9 activation in the development and healing of ethanol-induced damage in the cornea of mice. MATERIALS AND METHODS Mouse corneal injury was induced by topical treatment with 20% ethanol. BLI was obtained from the ocular region of mice intravenously injected with an active-MMP-2/9 probe. In vivo results were validated in primary corneal epithelial cells. RESULTS BLI indicated that treatment of the eye with 20% ethanol elevated MMP-2/9 activity, which was inhibited by the application of eye drops (hyaluronic acid and serum). Treatment of corneal epithelial cells with 20% ethanol-increased the activities of MMP-2 and MMP-9, which were also inhibited by eye drops. CONCLUSION BLI can be applied in vivo in mice with corneal injury to examine the activity of MMPs and clarify the efficacy of eye drops.
Collapse
Affiliation(s)
- Seung-Bo Park
- Department of Physiology, Konkuk University School of Medicine, Seoul, Republic of Korea
| | - Seung Hyo Jung
- Department of Physiology, Konkuk University School of Medicine, Seoul, Republic of Korea
| | - Hengzhe Jin
- Department of Physiology, Konkuk University School of Medicine, Seoul, Republic of Korea
| | - Su Jung Kim
- Department of Physiology, Konkuk University School of Medicine, Seoul, Republic of Korea
| | - Yunkyoung Ryu
- Department of Physiology, Konkuk University School of Medicine, Seoul, Republic of Korea
| | - Kyung-Jin Lee
- Department of Physiology, Konkuk University School of Medicine, Seoul, Republic of Korea
| | - Bokyung Kim
- Department of Physiology, Konkuk University School of Medicine, Seoul, Republic of Korea
| | - Hyun Jin Shin
- Department of Ophthalmology, Konkuk Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea
| | - Kyung-Jong Won
- Department of Physiology, Konkuk University School of Medicine, Seoul, Republic of Korea;
| |
Collapse
|
6
|
Sayah DN, Zhou TE, Omri S, Mazzaferri J, Quiniou C, Wirth M, Côté F, Dabouz R, Desjarlais M, Costantino S, Chemtob S. Novel Anti-Interleukin-1β Therapy Preserves Retinal Integrity: A Longitudinal Investigation Using OCT Imaging and Automated Retinal Segmentation in Small Rodents. Front Pharmacol 2020; 11:296. [PMID: 32226385 PMCID: PMC7081735 DOI: 10.3389/fphar.2020.00296] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2019] [Accepted: 02/27/2020] [Indexed: 12/16/2022] Open
Abstract
Retinopathy of prematurity (ROP) is the leading cause of blindness in neonates. Inflammation, in particular interleukin-1β (IL-1β), is increased in early stages of the disorder, and contributes to inner and outer retinal vasoobliteration in the oxygen-induced retinopathy (OIR) model of ROP. A small peptide antagonist of IL-1 receptor, composed of the amino acid sequence, rytvela, has been shown to exert beneficial anti-inflammatory effects without compromising immunovigilance-related NF-κB in reproductive tissues. We conducted a longitudinal study to determine the efficacy of “rytvela” in preserving the integrity of the retina in OIR model, using optical coherence tomography (OCT) which provides high-resolution cross-sectional imaging of ocular structures in vivo. Sprague–Dawley rats subjected to OIR and treated or not with “rytvela” were compared to IL-1 receptor antagonist (Kineret). OCT imaging and custom automated segmentation algorithm used to measure retinal thickness (RT) were obtained at P14 and P30; gold-standard immunohistochemistry (IHC) was used to confirm retinal anatomical changes. OCT revealed significant retinal thinning in untreated animals by P30, confirmed by IHC; these changes were coherently associated with increased apoptosis. Both rytvela and Kineret subsided apoptosis and preserved RT. As anticipated, Kineret diminished both SAPK/JNK and NF-κB axes, whereas rytvela selectively abated the former which resulted in preserved monocyte phagocytic function. Altogether, OCT imaging with automated segmentation is a reliable non-invasive approach to study longitudinally retinal pathology in small animal models of retinopathy.
Collapse
Affiliation(s)
- Diane N Sayah
- Hopital Maisonneuve-Rosemont Research Center, Montreal, QC, Canada.,Department of Ophthalmology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada
| | - Tianwei E Zhou
- Hopital Maisonneuve-Rosemont Research Center, Montreal, QC, Canada.,Department of Ophthalmology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.,Faculty of Medicine, McGill University, Montreal, QC, Canada
| | - Samy Omri
- Hopital Maisonneuve-Rosemont Research Center, Montreal, QC, Canada.,Department of Ophthalmology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada
| | | | - Christiane Quiniou
- Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine Research Center, Université de Montréal, Montreal, QC, Canada
| | - Maëlle Wirth
- Hopital Maisonneuve-Rosemont Research Center, Montreal, QC, Canada.,Department of Ophthalmology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada
| | - France Côté
- Hopital Maisonneuve-Rosemont Research Center, Montreal, QC, Canada.,Department of Ophthalmology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada
| | - Rabah Dabouz
- Hopital Maisonneuve-Rosemont Research Center, Montreal, QC, Canada.,Department of Ophthalmology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.,Faculty of Medicine, McGill University, Montreal, QC, Canada
| | - Michel Desjarlais
- Hopital Maisonneuve-Rosemont Research Center, Montreal, QC, Canada.,Department of Ophthalmology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada
| | - Santiago Costantino
- Hopital Maisonneuve-Rosemont Research Center, Montreal, QC, Canada.,Department of Ophthalmology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada
| | - Sylvain Chemtob
- Hopital Maisonneuve-Rosemont Research Center, Montreal, QC, Canada.,Department of Ophthalmology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.,Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine Research Center, Université de Montréal, Montreal, QC, Canada
| |
Collapse
|
7
|
Dimaras H, Corson TW. Retinoblastoma, the visible CNS tumor: A review. J Neurosci Res 2019; 97:29-44. [PMID: 29314142 PMCID: PMC6034991 DOI: 10.1002/jnr.24213] [Citation(s) in RCA: 109] [Impact Index Per Article: 21.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2017] [Revised: 12/02/2017] [Accepted: 12/11/2017] [Indexed: 12/11/2022]
Abstract
The pediatric ocular cancer retinoblastoma is the only central nervous system (CNS) tumor readily observed without specialized equipment: it can be seen by, and in, the naked eye. This accessibility enables unique imaging modalities. Here, we review this cancer for a neuroscience audience, highlighting these clinical and research imaging options, including fundus imaging, optical coherence tomography, ultrasound, and magnetic resonance imaging. We also discuss the subtype of retinoblastoma driven by the MYCN oncogene more commonly associated with neuroblastoma, and consider trilateral retinoblastoma, in which an intracranial tumor arises along with ocular tumors in patients with germline RB1 gene mutations. Retinoblastoma research and clinical care can offer insights applicable to CNS malignancies, and also benefit from approaches developed elsewhere in the CNS.
Collapse
Affiliation(s)
- Helen Dimaras
- Department of Ophthalmology and Vision Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, M5S 1A8, Canada
- Division of Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, M5S 1A8, Canada
- Department of Ophthalmology and Vision Sciences, The Hospital for Sick Children, Toronto, ON, M5G 1X8, Canada
- Child Health Evaluative Sciences Program, SickKids Research Institute, Toronto, ON, M5G 1X8, Canada
- Department of Human Pathology, College of Health Sciences, University of Nairobi, Nairobi, Kenya
| | - Timothy W. Corson
- Eugene and Marilyn Glick Eye Institute, Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
- Department of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, 46202, USA
| |
Collapse
|
8
|
Elshaer SL, Evans W, Pentecost M, Lenin R, Periasamy R, Jha KA, Alli S, Gentry J, Thomas SM, Sohl N, Gangaraju R. Adipose stem cells and their paracrine factors are therapeutic for early retinal complications of diabetes in the Ins2 Akita mouse. Stem Cell Res Ther 2018; 9:322. [PMID: 30463601 PMCID: PMC6249931 DOI: 10.1186/s13287-018-1059-y] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2018] [Revised: 10/05/2018] [Accepted: 10/23/2018] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Early-stage diabetic retinopathy (DR) is characterized by neurovascular defects. In this study, we hypothesized that human adipose-derived stem cells (ASCs) positive for the pericyte marker CD140b, or their secreted paracrine factors, therapeutically rescue early-stage DR features in an Ins2Akita mouse model. METHODS Ins2Akita mice at 24 weeks of age received intravitreal injections of CD140b-positive ASCs (1000 cells/1 μL) or 20× conditioned media from cytokine-primed ASCs (ASC-CM, 1 μL). Age-matched wildtype mice that received saline served as controls. Visual function experiments and histological analyses were performed 3 weeks post intravitreal injection. Biochemical and molecular analyses assessed the ASC-CM composition and its biological effects. RESULTS Three weeks post-injection, Ins2Akita mice that received ASCs had ameliorated decreased b-wave amplitudes and vascular leakage but failed to improve visual acuity, whereas Ins2Akita mice that received ASC-CM demonstrated amelioration of all aforementioned visual deficits. The ASC-CM group demonstrated partial amelioration of retinal GFAP immunoreactivity and DR-related gene expression but the ASC group did not. While Ins2Akita mice that received ASCs exhibited occasional (1 in 8) hemorrhagic retinas, mice that received ASC-CM had no adverse complications. In vitro, ASC-CM protected against TNFα-induced retinal endothelial permeability as measured by transendothelial electrical resistance. Biochemical and molecular analyses demonstrated several anti-inflammatory proteins including TSG-6 being highly expressed in cytokine-primed ASC-CM. CONCLUSIONS ASCs or their secreted factors mitigate retinal complications of diabetes in the Ins2Akita model. Further investigation is warranted to determine whether ASCs or their secreted factors are safe and effective therapeutic modalities long-term as current locally delivered therapies fail to effectively mitigate the progression of early-stage DR. Nonetheless, our study sheds new light on the therapeutic mechanisms of adult stem cells, with implications for assessing relative risks/benefits of experimental regenerative therapies for vision loss.
Collapse
Affiliation(s)
- Sally L. Elshaer
- Ophthalmology, University of Tennessee Health Science Center, 930 Madison Ave, Suite#768, Memphis, TN 38163 USA
- Pharmacology & Toxicology Department, College of Pharmacy, Mansoura University, Mansoura, Egypt
| | - William Evans
- Ophthalmology, University of Tennessee Health Science Center, 930 Madison Ave, Suite#768, Memphis, TN 38163 USA
| | | | - Raji Lenin
- Ophthalmology, University of Tennessee Health Science Center, 930 Madison Ave, Suite#768, Memphis, TN 38163 USA
| | - Ramesh Periasamy
- Ophthalmology, University of Tennessee Health Science Center, 930 Madison Ave, Suite#768, Memphis, TN 38163 USA
| | - Kumar Abhiram Jha
- Ophthalmology, University of Tennessee Health Science Center, 930 Madison Ave, Suite#768, Memphis, TN 38163 USA
| | - Shanta Alli
- Ophthalmology, University of Tennessee Health Science Center, 930 Madison Ave, Suite#768, Memphis, TN 38163 USA
| | - Jordy Gentry
- Ophthalmology, University of Tennessee Health Science Center, 930 Madison Ave, Suite#768, Memphis, TN 38163 USA
| | - Samuel M. Thomas
- Ophthalmology, University of Tennessee Health Science Center, 930 Madison Ave, Suite#768, Memphis, TN 38163 USA
| | - Nicolas Sohl
- Cell Care Therapeutics, Inc., Monrovia, CA 91016 USA
| | - Rajashekhar Gangaraju
- Ophthalmology, University of Tennessee Health Science Center, 930 Madison Ave, Suite#768, Memphis, TN 38163 USA
- Anatomy and Neurobiology, University of Tennessee Health Science Center, Memphis, TN 38163 USA
| |
Collapse
|
9
|
Song C, Zhang Q. Experimental animal study of docetaxel combined with carboplatin in the treatment of retinoblastoma. Oncol Lett 2018; 16:235-238. [PMID: 29928406 PMCID: PMC6006455 DOI: 10.3892/ol.2018.8623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2018] [Accepted: 04/25/2018] [Indexed: 11/05/2022] Open
Abstract
The synergistic effects of docetaxel (DTX) combined with carboplatin in the treatment of retinoblastoma (RB) was explored in mouse RB xenografts compared with carboplatin alone and DTX alone groups. Retinoblastoma Y-79 cells (4.0×107/ml) were injected into the vitreous body of the right eye of mice to establish the mouse model of RB xenografts. Then the mice were randomly divided into 4 groups (n=30): DTX combined with carboplatin group (group A), carboplatin group (group B), DTX group (group C) and blank control group (group D). The changes in tumors, the survival time of mice, and the synergistic effects of DTX combined with carboplatin were observed and analyzed. The diameters and weight of the right eyeballs of the Institute for Cancer Research (ICR) mice were significantly larger and higher than those of the left eyeballs in each group, respectively (P<0.05). The diameters and weight in group A were significantly shorter and lighter than those in the other three groups, respectively (P<0.05), and there was no significant difference compared with that of normal eyeballs (P>0.05). There was no difference in diameter and weight between group B and group C (P>0.05), but the diameters and weight were shorter and lighter than those in group D, respectively (P<0.05). The survival time of ICR mice in groups A, B and C was significantly longer than that in group D (P<0.05). The survival time in group A was significantly longer than that in groups B and C (P<0.05). There was no significant difference in the survival time between the group B and group C (P>0.05). DTX, carboplatin and the combination of the two have significant inhibitory effects on RB; however, DTX combined with carboplatin has a better therapeutic effect on RB.
Collapse
Affiliation(s)
- Caiping Song
- Department of Ophthalmology, Weihai Municipal Hospital, Weihai, Shandong 264200, P.R. China
| | - Qiang Zhang
- Department of Ophthalmology, Yantai Hospital of Traditional Chinese Medicine, Yantai, Shandong 264000, P.R. China
| |
Collapse
|
10
|
Maronpot RR, Nyska A, Troth SP, Gabrielson K, Sysa-Shah P, Kalchenko V, Kuznetsov Y, Harmelin A, Schiffenbauer YS, Bonnel D, Stauber J, Ramot Y. Regulatory Forum Opinion Piece*: Imaging Applications in Toxicologic Pathology-Recommendations for Use in Regulated Nonclinical Toxicity Studies. Toxicol Pathol 2018. [PMID: 28641506 DOI: 10.1177/0192623317710014] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Available imaging systems for use in preclinical toxicology studies increasingly show utility as important tools in the toxicologic pathologist's armamentarium, permit longitudinal evaluation of functional and morphological changes in tissues, and provide important information such as organ and lesion volume not obtained by conventional toxicology study parameters. Representative examples of practical imaging applications in toxicology research and preclinical studies are presented for ultrasound, positron emission tomography/single-photon emission computed tomography, optical, magnetic resonance imaging, and matrix-assisted laser desorption ionization-imaging mass spectrometry imaging. Some of the challenges for making imaging systems good laboratory practice-compliant for regulatory submission are presented. Use of imaging data on a case-by-case basis as part of safety evaluation in regulatory submissions is encouraged.
Collapse
Affiliation(s)
| | - Abraham Nyska
- 2 Toxicologic Pathology, Sackler School of Medicine, Tel Aviv University, Timrat, Israel
| | - Sean P Troth
- 3 Merck & Co., Inc., West Point, Pennsylvania, USA
| | - Kathleen Gabrielson
- 4 Department of Molecular and Comparative Pathobiology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| | - Polina Sysa-Shah
- 4 Department of Molecular and Comparative Pathobiology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| | - Vyacheslav Kalchenko
- 5 Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel
| | - Yuri Kuznetsov
- 5 Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel
| | - Alon Harmelin
- 5 Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel
| | | | | | | | - Yuval Ramot
- 8 Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| |
Collapse
|
11
|
Krishnaswami V, Kandasamy R, Alagarsamy S, Palanisamy R, Natesan S. Biological macromolecules for ophthalmic drug delivery to treat ocular diseases. Int J Biol Macromol 2018; 110:7-16. [DOI: 10.1016/j.ijbiomac.2018.01.120] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2017] [Revised: 01/10/2018] [Accepted: 01/17/2018] [Indexed: 12/31/2022]
|
12
|
|
13
|
Kailayangiri S, Altvater B, Spurny C, Jamitzky S, Schelhaas S, Jacobs AH, Wiek C, Roellecke K, Hanenberg H, Hartmann W, Wiendl H, Pankratz S, Meltzer J, Farwick N, Greune L, Fluegge M, Rossig C. Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. Oncoimmunology 2016; 6:e1250050. [PMID: 28197367 DOI: 10.1080/2162402x.2016.1250050] [Citation(s) in RCA: 81] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2016] [Revised: 10/13/2016] [Accepted: 10/13/2016] [Indexed: 12/22/2022] Open
Abstract
Activated and in vitro expanded natural killer (NK) cells have substantial cytotoxicity against many tumor cells, but their in vivo efficacy to eliminate solid cancers is limited. Here, we used chimeric antigen receptors (CARs) to enhance the activity of NK cells against Ewing sarcomas (EwS) in a tumor antigen-specific manner. Expression of CARs directed against the ganglioside antigen GD2 in activated NK cells increased their responses to GD2+ allogeneic EwS cells in vitro and overcame resistance of individual cell lines to NK cell lysis. Second-generation CARs with 4-1BB and 2B4 co-stimulatory signaling and third-generation CARs combining both co-stimulatory domains were all equally effective. By contrast, adoptive transfer of GD2-specific CAR gene-modified NK cells both by intratumoral and intraperitoneal delivery failed to eliminate GD2-expressing EwS xenografts. Histopathology review revealed upregulation of the immunosuppressive ligand HLA-G in tumor autopsies from mice treated with NK cells compared to untreated control mice. Supporting the relevance of this finding, in vitro co-incubation of NK cells with allogeneic EwS cells induced upregulation of the HLA-G receptor CD85j, and HLA-G1 expressed by EwS cells suppressed the activity of NK cells from three of five allogeneic donors against the tumor cells in vitro. We conclude that HLA-G is a candidate immune checkpoint in EwS where it can contribute to resistance to NK cell therapy. HLA-G deserves evaluation as a potential target for more effective immunotherapeutic combination regimens in this and other cancers.
Collapse
Affiliation(s)
- Sareetha Kailayangiri
- Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster , Muenster, Germany
| | - Bianca Altvater
- Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster , Muenster, Germany
| | - Christian Spurny
- Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster , Muenster, Germany
| | - Silke Jamitzky
- Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster , Muenster, Germany
| | - Sonja Schelhaas
- European Institute for Molecular Imaging (EIMI), University of Muenster , Muenster, Germany
| | - Andreas H Jacobs
- European Institute for Molecular Imaging (EIMI), University of Muenster, Muenster, Germany; Cells-in-Motion Cluster of Excellence (EXC 1003 - CiM), University of Muenster, Muenster, Germany
| | - Constanze Wiek
- Department of Otorhinolaryngology, Head and Neck Surgery, Children's Hospital, Heinrich Heine University , Duesseldorf, Germany
| | - Katharina Roellecke
- Department of Otorhinolaryngology, Head and Neck Surgery, Children's Hospital, Heinrich Heine University , Duesseldorf, Germany
| | - Helmut Hanenberg
- Department of Otorhinolaryngology, Head and Neck Surgery, Children's Hospital, Heinrich Heine University, Duesseldorf, Germany; Department of Pediatrics III, University Children's Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Wolfgang Hartmann
- Gerhard-Domagk Institute for Pathology, University of Muenster , Muenster, Germany
| | - Heinz Wiendl
- Cells-in-Motion Cluster of Excellence (EXC 1003 - CiM), University of Muenster, Muenster, Germany; Department of Neurology, University Hospital Muenster, Muenster, Germany
| | - Susann Pankratz
- Department of Neurology, University Hospital Muenster , Muenster, Germany
| | - Jutta Meltzer
- Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster , Muenster, Germany
| | - Nicole Farwick
- Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster , Muenster, Germany
| | - Lea Greune
- Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster , Muenster, Germany
| | - Maike Fluegge
- Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster , Muenster, Germany
| | - Claudia Rossig
- Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany; Cells-in-Motion Cluster of Excellence (EXC 1003 - CiM), University of Muenster, Muenster, Germany
| |
Collapse
|
14
|
O'Hare M, Shadmand M, Sulaiman RS, Sishtla K, Sakisaka T, Corson TW. Kif14 overexpression accelerates murine retinoblastoma development. Int J Cancer 2016; 139:1752-8. [PMID: 27270502 DOI: 10.1002/ijc.30221] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Revised: 05/10/2016] [Accepted: 05/25/2016] [Indexed: 12/28/2022]
Abstract
The mitotic kinesin KIF14 has an essential role in the recruitment of proteins required for the final stages of cytokinesis. Genomic gain and/or overexpression of KIF14 has been documented in retinoblastoma and a number of other cancers, such as breast, lung and ovarian carcinomas, strongly suggesting its role as an oncogene. Despite evidence of oncogenic properties in vitro and in xenografts, Kif14's role in tumor progression has not previously been studied in a transgenic cancer model. Using a novel Kif14 overexpressing, simian virus 40 large T-antigen retinoblastoma (TAg-RB) double transgenic mouse model, we aimed to determine Kif14's role in promoting retinal tumor formation. Tumor initiation and development in double transgenics and control TAg-RB littermates were documented in vivo over a time course by optical coherence tomography, with subsequent ex vivo quantification of tumor burden. Kif14 overexpression led to an accelerated initiation of tumor formation in the TAg-RB model and a significantly decreased tumor doubling time (1.8 vs. 2.9 weeks). Moreover, overall percentage tumor burden was also increased by Kif14 overexpression. These data provide the first evidence that Kif14 can promote tumor formation in susceptible cells in vivo.
Collapse
Affiliation(s)
- Michael O'Hare
- Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN.,Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN.,Biomedical Science, University of Ulster, Coleraine, United Kingdom
| | - Mehdi Shadmand
- Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN.,Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN
| | - Rania S Sulaiman
- Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN.,Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN.,Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN.,Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt
| | - Kamakshi Sishtla
- Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN.,Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN
| | - Toshiaki Sakisaka
- Division of Membrane Dynamics, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Timothy W Corson
- Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN.,Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN.,Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN.,Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN.,Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA
| |
Collapse
|
15
|
Bone Marrow-Derived Cells as a Therapeutic Approach to Optic Nerve Diseases. Stem Cells Int 2015; 2016:5078619. [PMID: 26649049 PMCID: PMC4663341 DOI: 10.1155/2016/5078619] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2015] [Accepted: 09/10/2015] [Indexed: 12/16/2022] Open
Abstract
Following optic nerve injury associated with acute or progressive diseases, retinal ganglion cells (RGCs) of adult mammals degenerate and undergo apoptosis. These diseases have limited therapeutic options, due to the low inherent capacity of RGCs to regenerate and due to the inhibitory milieu of the central nervous system. Among the numerous treatment approaches investigated to stimulate neuronal survival and axonal extension, cell transplantation emerges as a promising option. This review focuses on cell therapies with bone marrow mononuclear cells and bone marrow-derived mesenchymal stem cells, which have shown positive therapeutic effects in animal models of optic neuropathies. Different aspects of available preclinical studies are analyzed, including cell distribution, potential doses, routes of administration, and mechanisms of action. Finally, published and ongoing clinical trials are summarized.
Collapse
|
16
|
Chen X, Wang J, Cao Z, Hosaka K, Jensen L, Yang H, Sun Y, Zhuang R, Liu Y, Cao Y. Invasiveness and metastasis of retinoblastoma in an orthotopic zebrafish tumor model. Sci Rep 2015; 5:10351. [PMID: 26169357 PMCID: PMC4501005 DOI: 10.1038/srep10351] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Accepted: 04/08/2015] [Indexed: 01/08/2023] Open
Abstract
Retinoblastoma is a highly invasive malignant tumor that often invades the brain and metastasizes to distal organs through the blood stream. Invasiveness and metastasis of retinoblastoma can occur at the early stage of tumor development. However, an optimal preclinical model to study retinoblastoma invasiveness and metastasis in relation to drug treatment has not been developed. Here, we developed an orthotopic zebrafish model in which retinoblastoma invasion and metastasis can be monitored at a single cell level. We took the advantages of immune privilege and transparent nature of developing zebrafish embryos. Intravitreal implantation of color-coded retinoblastoma cells allowed us to kinetically monitor tumor cell invasion and metastasis. Further, interactions between retinoblastoma cells and surrounding microvasculatures were studied using a transgenic zebrafish that exhibited green fluorescent signals in blood vessels. We discovered that tumor cells invaded neighboring tissues and blood stream when primary tumors were at the microscopic sizes. These findings demonstrate that retinoblastoma metastasis occurs at the early stage and antiangiogenic drugs such as Vegf morpholino and sunitinib could potentially interfere with tumor invasiveness and metastasis. Thus, this orthotopic retinoblastoma model offers a new and unique opportunity to study the early events of tumor invasion, metastasis and drug responses.
Collapse
Affiliation(s)
- Xiaoyun Chen
- 1] The State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guanzhou, 510060, People's Republic of China [2] Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77 Stockholm, Sweden
| | - Jian Wang
- 1] Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77 Stockholm, Sweden [2] Department of Oncology, Jinan Central Hospital, Shandong University, NO.105, Jiefang Road, Jinan, Shandong 250013, People's Republic of China
| | - Ziquan Cao
- 1] Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77 Stockholm, Sweden [2] Department of Medicine and Health Sciences, Linköping University, 581 83. Linköping, Sweden
| | - Kayoko Hosaka
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77 Stockholm, Sweden
| | - Lasse Jensen
- 1] Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77 Stockholm, Sweden [2] Department of Medicine and Health Sciences, Linköping University, 581 83. Linköping, Sweden
| | - Huasheng Yang
- The State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guanzhou, 510060, People's Republic of China
| | - Yuping Sun
- Department of Oncology, Jinan Central Hospital, Shandong University, NO.105, Jiefang Road, Jinan, Shandong 250013, People's Republic of China
| | - Rujie Zhuang
- Zhejiang First affiliated Hospital of Chinese Medical University, Hangzhou, 310006, People´s Republic of China
| | - Yizhi Liu
- The State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guanzhou, 510060, People's Republic of China
| | - Yihai Cao
- 1] Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77 Stockholm, Sweden [2] Department of Medicine and Health Sciences, Linköping University, 581 83. Linköping, Sweden [3] Department of Cardiovascular Sciences, University of Leicester and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, LE3 9QP, UK
| |
Collapse
|
17
|
Sulaiman RS, Quigley J, Qi X, O'Hare MN, Grant MB, Boulton ME, Corson TW. A Simple Optical Coherence Tomography Quantification Method for Choroidal Neovascularization. J Ocul Pharmacol Ther 2015; 31:447-54. [PMID: 26060878 DOI: 10.1089/jop.2015.0049] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
PURPOSE Therapeutic efficacy is routinely assessed by measurement of lesion size using flatmounted choroids and confocal microscopy in the laser-induced choroidal neovascularization (L-CNV) rodent model. We investigated whether optical coherence tomography (OCT) quantification, using an ellipsoid volume measurement, was comparable to standard ex vivo evaluation methods for this model and whether this approach could be used to monitor treatment-related lesion changes. METHODS Bruch's membrane was ruptured by argon laser in the dilated eyes of C57BL/6J mice, followed by intravitreal injections of anti-VEGF164 or vehicle, or no injection. In vivo OCT images were acquired using Micron III or InVivoVue systems at 7, 10, and/or 14 days post-laser and neovascular lesion volume was calculated as an ellipsoid. Subsequently, lesion volume was compared to that calculated from confocal Z-stack images of agglutinin-stained choroidal flatmounts. RESULTS Ellipsoid volume measurement of orthogonal 2-dimensional OCT images obtained from different imaging systems correlated with ex vivo lesion volumes for L-CNV (Spearman's ρ=0.82, 0.75, and 0.82 at days 7, 10, and 14, respectively). Ellipsoid volume calculation allowed temporal monitoring and evaluation of CNV lesions in response to antivascular endothelial growth factor treatment. CONCLUSIONS Ellipsoid volume measurements allow rapid, quantitative use of OCT for the assessment of CNV lesions in vivo. This novel method can be used with different OCT imaging systems with sensitivity to distinguish between treatment conditions. It may serve as a useful adjunct to the standard ex vivo confocal quantification, to assess therapeutic efficacy in preclinical models of CNV, and in models of other ocular diseases.
Collapse
Affiliation(s)
- Rania S Sulaiman
- 1 Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine , Indianapolis, Indiana.,2 Department of Ophthalmology, Indiana University School of Medicine , Indianapolis, Indiana.,3 Department of Pharmacology and Toxicology, Indiana University School of Medicine , Indianapolis, Indiana.,4 Department of Biochemistry, Faculty of Pharmacy, Cairo University , Cairo, Egypt
| | - Judith Quigley
- 1 Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine , Indianapolis, Indiana.,2 Department of Ophthalmology, Indiana University School of Medicine , Indianapolis, Indiana
| | - Xiaoping Qi
- 1 Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine , Indianapolis, Indiana.,2 Department of Ophthalmology, Indiana University School of Medicine , Indianapolis, Indiana
| | - Michael N O'Hare
- 1 Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine , Indianapolis, Indiana.,2 Department of Ophthalmology, Indiana University School of Medicine , Indianapolis, Indiana.,5 School of Biomedical Science, University of Ulster , Coleraine, Northern Ireland, United Kingdom
| | - Maria B Grant
- 1 Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine , Indianapolis, Indiana.,2 Department of Ophthalmology, Indiana University School of Medicine , Indianapolis, Indiana
| | - Michael E Boulton
- 1 Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine , Indianapolis, Indiana.,2 Department of Ophthalmology, Indiana University School of Medicine , Indianapolis, Indiana
| | - Timothy W Corson
- 1 Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine , Indianapolis, Indiana.,2 Department of Ophthalmology, Indiana University School of Medicine , Indianapolis, Indiana.,3 Department of Pharmacology and Toxicology, Indiana University School of Medicine , Indianapolis, Indiana.,6 Department of Biochemistry and Molecular Biology, Indiana University School of Medicine , Indianapolis, Indiana.,7 Indiana University Melvin and Bren Simon Cancer Center , Indianapolis, Indiana
| |
Collapse
|
18
|
Wenzel AA, O’Hare MN, Shadmand M, Corson TW. Optical coherence tomography enables imaging of tumor initiation in the TAg-RB mouse model of retinoblastoma. Mol Vis 2015; 21:515-22. [PMID: 25999678 PMCID: PMC4440496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2015] [Accepted: 04/29/2015] [Indexed: 11/30/2022] Open
Abstract
PURPOSE Retinoblastoma is the most common primary intraocular malignancy in children. Although significant advances in treatment have decreased mortality in recent years, morbidity continues to be associated with these therapies, and therefore, there is a pressing need for new therapeutic options. Transgenic mouse models are popular for testing new therapeutics as well as studying the pathophysiology of retinoblastoma. The T-antigen retinoblastoma (TAg-RB) model has close molecular and histological resemblance to human retinoblastoma tumors; these mice inactivate pRB by retinal-specific expression of the Simian Virus 40 T-antigens. Here, we evaluated whether optical coherence tomography (OCT) imaging could be used to document tumor growth in the TAg-RB model from the earliest stages of tumor development. METHODS The Micron III rodent imaging system was used to obtain fundus photographs and OCT images of both eyes of TAg-RB mice weekly from 2 to 12 weeks of age and at 16 and 20 weeks of age to document tumor development. Tumor morphology was confirmed with histological analysis. RESULTS Before being visible on funduscopy, hyperreflective masses arising in the inner nuclear layer were evident at 2 weeks of age with OCT imaging. After most of these hyperreflective cell clusters disappeared around 4 weeks of age, the first tumors became visible on OCT and funduscopy by 6 weeks. The masses grew into discrete, discoid tumors, preferentially in the periphery, that developed more irregular morphology over time, eventually merging and displacing the inner retinal layers into the vitreous. CONCLUSIONS OCT is a non-invasive imaging modality for tracking early TAg-RB tumor growth in vivo. Using OCT, we characterized TAg-positive cells as early as 2 weeks, corresponding to the earliest stages at which tumors are histologically evident, and well before they are evident with funduscopy. Tracking tumor growth from its earliest stages will allow better analysis of the efficacy of novel therapeutics and genetic factors tested in this powerful mouse model.
Collapse
Affiliation(s)
- Andrea A. Wenzel
- Eugene and Marilyn Glick Eye Institute, Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN
| | - Michael N. O’Hare
- Eugene and Marilyn Glick Eye Institute, Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN,School of Biomedical Science, University of Ulster, Coleraine, Northern Ireland, UK
| | - Mehdi Shadmand
- Eugene and Marilyn Glick Eye Institute, Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN
| | - Timothy W. Corson
- Eugene and Marilyn Glick Eye Institute, Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN,Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN,Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN,Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| |
Collapse
|